CME information

The University of Cincinnati designates this educational activity for a maximum of 1 AMA PRA Category 1 credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.

This activity has been planned and implemented in accordance with the Essentials and Policies of the Accreditation Council for Continuing Medical Education (ACCME). The University of Cincinnati, College of Medicine Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians. The University of Cincinnati College of Medicine takes responsibility for the content, quality and scientific integrity of this CME activity

Core Faculty

The content presented at this program was established by the following core faculty members:


John R. Lake, MD

Program Chair
Professor of Medicine and Surgery
University of Minnesota Medical Center
Minneapolis, Minnesota
 

Mark Barr, MD
Associate Professor of Surgery
University of Southern California
Keck School of Medicine
Los Angeles, California

Daniel C. Brennan, MD
Professor of Medicine
Washington University
St. Louis, Missouri
 

Robert Ettenger, MD
Casey Lee Ball Distinguished Professor of Pediatrics
Head, Division of Nephrology
Medical Director, Pediatric Kidney Transplant Program
Mattel Childrens Hospital at UCLA
David Geffen School of Medicine at UCLA

Sundaram Hariharan, MD
Professor of Medicine
Chief of Nephrology Division
Froedtert & Medical College of Wisconsin
Milwaukee, Wisconsin
 

Mysore S. Anil Kumar, MD
Professor of Surgery
Chief, Division of Transplantation
Drexel University College of Medicine
Hahnemann University Hospital
Philadelphia, Pennsylvania

Arthur J. Matas, MD
Professor of Surgery
University of Minnesota
Minneapolis, Minnesota

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The University of Cincinnati and SynerMed Communications do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati and SynerMed Communications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Everolimus is an investigational drug and is not yet available for commercial use.

DISCLOSURE STATEMENT

The University of Cincinnati is committed to offering CME programs that promote improvements of quality in healthcare and are developed free of the control of commercial interests. Faculty and course directors have disclosed all relevant financial relationships with commercial companies, and the University of Cincinnati has a process in place to resolve any conflict of interest. University of Cincinnati also requires that faculty disclose any discussion of off-label investigational uses included in their presentations. Disclosure of a relationship is not intended to suggest or condone bias in a presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Name of Faculty or Presenter
Reported Financial Relationship
Mark Barr, MD
No Reported Financial Relationship
Daniel Brennan, MD




 
Astellas Pharma, Inc
Genzyme Corp
Hoffman-LaRoche Inc
Novartis Pharmaceuticals
Pfizer Inc
Wyeth Pharmaceuticals
Robert Ettenger, MD
No Reported Financial Relationship
Sudaram Hariharan, MD
No Reported Financial Relationship
Mysore Anil Kumar, MD
Novartis Pharmaceuticals
Jack Lake, MD



Astellas Pharma Inc
Hoffman-LaRoche Inc
Novartis Pharmaceuticals
Wyeth Pharmaceuticals
Arthur Matas, MD




Astellas Pharma Inc
Genzyme Corp
Hoffman-LaRoche Inc
Novartis Pharmaceuticals
Wyeth Pharmaceuticals

JOINT SPONSOR DISCLOSURE STATEMENT

University of Cincinnati Center for Continuous Professional Development and SynerMed Communications staff involved in the development of this activity have no financial relationships with any commercial interest that are relevant to this activity.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, The University of Cincinnati. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this activity. During the period May, 2008 to May 31, 2009, participants must (1) read the educational objectives and faculty disclosures, (2) study the educational activity, (3) complete the posttest by recording the best answer to each question, (4) complete the evaluation form, and (5) mail or fax the evaluation form with answer key to the University of Cincinnati or complete the posttest and evaluation on-line by clicking here. A certificate of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Your certificate of credit will be mailed to you within 3-5 weeks.

audio slideshow
Listen to or download our podcast and view the slideshow.

Find Out How
information